Minimal Residual Disease (Mrd) Status In Fcr-Treated Cll Patients At The End Of Treatment Influences Progression Free Survival (Pfs), Results Of The Ctrial-Ie (Icorg) 07-01/Cll Ireland Study, With Mutational Analysis Providing Additional Insight

Fludarabine, cyclophosphamide and rituximab (FCR) therapy results in a complete remission (CR) rate of 72% and a median progression free survival (PFS) of 80 months in non-del (17P) CLL1. Achieving an MRD negative (MRD-ve) CR after completing therapy is an early surrogate marker for overall survival (OS) and PFS2. Specific genetic CLL subtypes determined by fluorescent in-situ hybridisation (FISH) analysis, immunoglobulin mutation IgVH, NOTCH1 and SF3B1 status determine response to chemotherapy3,4.